Naoya Uchida

List of Publications by Year
in descending order

73	1,813	279487 23	301761 39
papers	citations	h-index	g-index

75	75	75	2284
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models. Cell Stem Cell, 2011, 8, 445-458.	5.2	250
2	Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Advances, 2019, 3, 3379-3392.	2.5	121
3	Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances, 2020, 4, 2058-2063.	2.5	93
4	Path to the Clinic: Assessment of iPSC-Based Cell Therapies InÂVivo in a Nonhuman Primate Model. Cell Reports, 2014, 7, 1298-1309.	2.9	84
5	Gene therapy for sickle cell disease: An update. Cytotherapy, 2018, 20, 899-910.	0.3	84
6	Busulfan Produces Efficient Human Cell Engraftment in NOD/LtSz-Scid IL2RÎ³ Null Mice. Stem Cells, 2009, 27, 175-182.	1.4	60
7	BCL11A enhancerâ€“edited hematopoietic stem cells persist in rhesus monkeys without toxicity. Journal of Clinical Investigation, 2020, 130, 6677-6687.	3.9	54
8	Development of a Human Immunodeficiency Virus Type 1-Based Lentiviral Vector That Allows Efficient Transduction of both Human and Rhesus Blood Cells. Journal of Virology, 2009, 83, 9854-9862.	1.5	53
9	Gene replacement of Î±-globin with Î²-globin restores hemoglobin balance in Î²-thalassemia-derived hematopoietic stem and progenitor cells. Nature Medicine, 2021, 27, 677-687.	15.2	51
10	Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery. British Journal of Haematology, 2019, 186, 286-299.	1.2	49
11	Î²-Globin-Expressing Definitive Erythroid Progenitor Cells Generated from Embryonic and Induced Pluripotent Stem Cell-Derived Sacs. Stem Cells, 2016, 34, 1541-1552.	1.4	48
12	Efficient Generation of Î²-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells from Patients with Sickle Cell Disease. Stem Cells, 2017, 35, 586-596.	1.4	39
13	CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges. Advances in Experimental Medicine and Biology, 2019, 1144, 37-52.	0.8	37
14	Chicken HS4 Insulators Have Minimal Barrier Function Among Progeny of Human Hematopoietic Cells Transduced With an HIV1-based Lentiviral Vector. Molecular Therapy, 2011, 19, 133-139.	3.7	36
15	Accelerated lymphocyte reconstitution and long-term recovery afterÂtransplantation of lentiviral-transduced rhesus CD34+ cells mobilizedÂbyÂG-CSF and plerixafor. Experimental Hematology, 2011, 39, 795-805.	0.2	34
16	Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque. Molecular Therapy, 2019, 27, 1074-1086.	3.7	34
17	High-efficiency Transduction of Rhesus Hematopoietic Repopulating Cells by a Modified HIV1-based Lentiviral Vector. Molecular Therapy, 2012, 20, 1882-1892.	3.7	33
18	High-Efficiency Lentiviral Transduction of Human CD34+ Cells in High-Density Culture with Poloxamer and Prostaglandin E2. Molecular Therapy - Methods and Clinical Development, 2019, 13, 187-196.	1.8	31

#	Article	IF	Citations
19	Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica, 2020, 105, e497.	1.7	29
20	Busulfan Combined with Immunosuppression Allows Efficient Engraftment of Gene-Modified Cells in a Rhesus Macaque Model. Molecular Therapy, 2019, 27, 1586-1596.	3.7	28
21	MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathway. Blood, 2013, 121, 3216-3227.	0.6	27
22	TRIM5Î± Variations Influence Transduction Efficiency With Lentiviral Vectors in Both Human and Rhesus CD34 + Cells In Vitro and In Vivo. Molecular Therapy, 2014, 22, 348-358.	3.7	26
23	Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia. Science Translational Medicine, 2017, 9, .	5.8	26
24	Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. Molecular Therapy - Methods and Clinical Development, 2021, 21, 121-132.	1.8	25
25	Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Advances, 2021, 5, 2403-2411.	2.5	24
26	Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients. Human Gene Therapy Clinical Development, 2017, 28, 136-144.	3.2	23
27	Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system. Stem Cell Research, 2019, 41, 101600.	0.3	23
28	Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders. Nature Communications, 2019, 10, 4479.	5.8	21
29	Low-Dose Busulfan Reduces Human CD34+ Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient Mice. Molecular Therapy - Methods and Clinical Development, 2019, 15, 430-437.	1.8	21
30	Integration-specific In Vitro Evaluation of Lentivirally Transduced Rhesus CD34+ Cells Correlates With In Vivo Vector Copy Number. Molecular Therapy - Nucleic Acids, 2013, 2, e122.	2.3	20
31	Leukemogenesis of b2a2-type p210 BCR/ABL in a Bone Marrow Transplantation Mouse Model Using a Lentiviral Vector. Journal of Nippon Medical School, 2009, 76, 134-147.	0.3	19
32	The Chicken Hypersensitivity Site 4 Core Insulator Blocks Promoter Interference in Lentiviral Vectors. Human Gene Therapy Methods, 2013, 24, 117-124.	2.1	17
33	Biallelic correction of sickle cell diseaseâ€derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serumâ€free iPSâ€sac/erythroid differentiation. Stem Cells Translational Medicine, 2020, 9, 590-602.	1.6	17
34	Hematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for Î²-hemoglobinopathies. Cell Stem Cell, 2021, 28, 191-208.	5.2	17
35	Immunoresponse to Gene-Modified Hematopoietic Stem Cells. Molecular Therapy - Methods and Clinical Development, 2020, 16, 42-49.	1.8	16
36	Discordance in lymphoid tissue recovery following stem cell transplantation in rhesus macaques: an in vivo imaging study. Blood, 2015, 126, 2632-2641.	0.6	15

#	Article	IF	Citations
37	Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models. Cell Reports Medicine, 2021, 2, 100247.	3.3	15
38	Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid. Experimental Hematology, 2013, 41, 779-788.e1.	0.2	14
39	A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates. Blood, 2019, 134, 610-610.	0.6	14
40	The Assessment of Human Erythroid Output in NOD/SCID Mice Reconstituted with Human Hematopoietic Stem Cells. Cell Transplantation, 2010, 19, 1465-1473.	1.2	13
41	SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders. Experimental Hematology, 2016, 44, 483-490.e2.	0.2	13
42	Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation. Stem Cell Research and Therapy, 2020, 11, 493.	2.4	13
43	Î²T87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for ExÂVivo Anti-sickling Activity in Human Erythroid Cells. Molecular Therapy - Methods and Clinical Development, 2020, 17, 912-921.	1.8	13
44	A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility forÂtesting interventions. Blood, 2022, 140, 1774-1789.	0.6	13
45	Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production. Molecular Therapy - Methods and Clinical Development, 2018, 9, 247-256.	1.8	12
46	Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease. Cells, 2022, 11, 1843.	1.8	12
47	Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16059.	1.8	10
48	High-level embryonic globin production with efficient erythroid differentiation from a K562 erythroleukemia cell line. Experimental Hematology, 2018, 62, 7-16.e1.	0.2	10
49	Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixaforâ€mobilized patients with sickle cell disease. British Journal of Haematology, 2022, 198, 740-744.	1.2	8
50	Kinetics of lentiviral vector transduction in human CD34+ cells. Experimental Hematology, 2016, 44, 106-115.	0.2	7
51	Robust erythroid differentiation system for rhesus hematopoietic progenitor cells allowing preclinical screening of genetic treatment strategies for the hemoglobinopathies. Cytotherapy, 2018, 20, 1278-1287.	0.3	6
52	Sustained fetal hemoglobin induction in vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor. Science Translational Medicine, 2021, 13, .	5.8	6
53	Durable and Robust Fetal Globin Induction without Anemia in Rhesus Monkeys Following Autologous Hematopoietic Stem Cell Transplant with BCL11A Erythroid Enhancer Editing. Blood, 2019, 134, 4632-4632.	0.6	6
54	Intrabone transplantation of CD34+ cells with optimized delivery does not enhance engraftment in a rhesus macaque model. Blood Advances, 2020, 4, 6148-6156.	2.5	5

#	Article	IF	Citations
55	Decitabine Suspends Human CD34+ Cell Differentiation and Proliferation during Lentiviral Transduction. PLoS ONE, 2014, 9, e104022.	1.1	4
56	No Impact of Lentiviral Transduction on Hematopoietic Stem/Progenitor Cell Telomere Length or Gene Expression in the Rhesus Macaque Model. Molecular Therapy, 2014, 22, 52-58.	3.7	4
57	Generation Of Mature Erythroid Cells From Human Embryonic Stem Cell Derived Sacs and Optimization Of Erythroid Cell Generation. Blood, 2013, 122, 2425-2425.	0.6	4
58	Bone Marrow Characterization in Sickle Cell Disease: Inflammation and Stress Erythropoiesis Lead to Suboptimal CD34 Recovery Compared to Normal Volunteer Bone Marrow. Blood, 2017, 130, 966-966.	0.6	4
59	RNA Trans-Splicing Targeting Endogenous Î²-Globin Pre-Messenger RNA in Human Erythroid Cells. Human Gene Therapy Methods, 2017, 28, 91-99.	2.1	3
60	Fetal hemoglobin and F-cell variance in mobilized CD34+ cell-transplanted rhesus monkeys. Experimental Hematology, 2019, 75, 21-25.e1.	0.2	3
61	Determining Limitations in Human CD34+ Cell Transduction with An HIV1-Based Lentiviral Vector,. Blood, 2011, 118, 4171-4171.	0.6	3
62	CD117 Antibody Drug Conjugate-Based Conditioning Allows for Efficient Engraftment of Gene-Modified CD34+ Cells in a Rhesus Gene Therapy Model. Blood, 2021, 138, 560-560.	0.6	3
63	Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model. Blood, 2019, 134, 609-609.	0.6	2
64	Truncated Erythropoietin Receptors Confer an In Vivo Selective Advantage in Gene-Modified Erythroid Cells Expressing Fetal Hemoglobin Due to BCL11A Interference. Blood, 2019, 134, 2063-2063.	0.6	2
65	Development of a New Generation, Forward-Oriented Therapeutic Vector for Hemoglobin Disorders. Blood, 2016, 128, 1172-1172.	0.6	2
66	Discordance Between Peripheral Blood and Tissue CD4+ Lymphocyte Reconstitution In Rhesus Monkeys Following Autologous Hematopoietic CD34+ Cell Transplantation: An In Vivo imaging Study. Blood, 2013, 122, 2019-2019.	0.6	2
67	Commentary on Winzeler et al â€˜Low arginine vasopressin levels in patients with diabetes insipidus are not associated with anaemiaâ€™. Clinical Endocrinology, 2021, 94, 888-890.	1.2	1
68	Leukemogenesis of the b2a2 Type p210 BCR/ABL in a Bone Marrow Transplantation Mouse Model Using a Lentivirus Vector.. Blood, 2005, 106, 2875-2875.	0.6	0
69	Hematopoietic Differentiation of ES Cells from P230 Bcr/Abl Transgenic Mouse.. Blood, 2005, 106, 4331-4331.	0.6	0
70	MLL-AF4 and FLT3 Activation Synergize To Induce Multi Step Leukemogenesis.. Blood, 2006, 108, 4321-4321.	0.6	0
71	Peripheral Blood As a Source Of Cells For Regenerative Medicine Applications In Sickle Cell Disease. Blood, 2013, 122, 2209-2209.	0.6	0
72	CD34+CXCR4(CD184)+ Cells Differentiate Into Myeloid Dendritic Cell Progenitors. Blood, 2013, 122, 4835-4835.	0.6	0

#	Article	IF	Citations
73	More Efficient Generation of Î²-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells. Blood, 2015, 126, 1150-1150.	0.6	0